<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Respirology/Interstitial%20Lung%20Disease/Idiopathic%20pulmonary%20fibrosis%20%28IPF%29/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Background - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Background", url: "#_top", children: [
          ]},
          {title: "Diagnosis of IPF", url: "#diagnosis-of-ipf", children: [
              {title: "Progressive Pulmonary Fibrosis (PPF)", url: "#progressive-pulmonary-fibrosis-ppf" },
          ]},
          {title: "Treatment of IPF", url: "#treatment-of-ipf", children: [
              {title: "Acute Exacerbations of IPF", url: "#acute-exacerbations-of-ipf" },
              {title: "Long-Term Management", url: "#long-term-management" },
              {title: "Transplant Referral", url: "#transplant-referral" },
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Interstitial%20Lung%20Disease/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Interstitial%20Lung%20Disease/" class="btn btn-xs btn-link">
        Classification of ILDs
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Hypersensitivity%20Pneumonitis/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Hypersensitivity%20Pneumonitis/" class="btn btn-xs btn-link">
        Hypersensitivity Pneumonitis
      </a>
    </div>
    
  </div>

    

    <h1 id="background">Background</h1>
<ul>
<li>the most common IIP</li>
<li>Epidemiology:<ul>
<li>M&gt;F</li>
<li>6th or 7th decade of life, rare &lt; 50</li>
</ul>
</li>
<li>Chronic, progressive, fibrotic ILD defined by the histologic/radiologic pattern of Usual Interstitial Pneumonia (UIP)</li>
</ul>
<h1 id="diagnosis-of-ipf">Diagnosis of IPF</h1>
<ul>
<li>Requires:<ul>
<li>exclusion of other known causes of ILD</li>
<li>demonstration of <strong>UIP pattern</strong> on HRCT<ul>
<li>subpleural, basal predominant reticular changes, often heterogenous distribution.</li>
<li>honeycombing +/- peripheral traction bronchiectasis or bronchiolectasis</li>
</ul>
</li>
<li>Specific combinations of HRCT pattern and histopathologic patterns in patients subject to tissue biopsy</li>
</ul>
</li>
<li>Send serologic testing: ANA, RF, anti-CCP, +/- myositis panel +/- Rheum referral.</li>
<li>MDD (multidisciplinary discussion) to decide whether further diagnosis (bronchoscopy and BAL, surgical lung biopsy, etc) are required</li>
</ul>
<p><img alt="" src="../_attachments/Pasted%20image%2020221026004230.png" /></p>
<h2 id="progressive-pulmonary-fibrosis-ppf">Progressive Pulmonary Fibrosis (PPF)</h2>
<p><img alt="" src="../_attachments/Pasted%20image%2020231010194534.png" /></p>
<h1 id="treatment-of-ipf">Treatment of IPF</h1>
<h2 id="acute-exacerbations-of-ipf">Acute Exacerbations of IPF</h2>
<p>Defined as worsening SOB, hypoxemia with new diffuse bilateral GGO on CT. </p>
<p>Management:
- Rule out infection/PE/HF
- Consider high dose steroids (1 g/d x 3 --&gt; 1 mg/kg PO daily) and empiric antimicrobials.
- Discuss goals of care: 50% in-hospital mortality</p>
<h2 id="long-term-management">Long-Term Management</h2>
<h3 id="non-targeted">Non-Targeted</h3>
<ol>
<li>Smoking cessation</li>
<li>Oxygen therapy</li>
<li>PPI</li>
<li>Pulmonary rehab</li>
<li>Vaccinations (Pneumococcus, influenza, COVID)</li>
<li>Advanced care planning</li>
</ol>
<h3 id="anti-fibrotic-medications">Anti-Fibrotic Medications</h3>
<p>Choice is mainly based on side effects and on patient preference.</p>
<table>
<thead>
<tr>
<th>Medication</th>
<th>Trials</th>
<th>MOA</th>
<th>Benefits</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nintendanib</td>
<td>INPULSIS 1/2</td>
<td>TK inhibitor</td>
<td>Reduces FVC decline, trend to reduced mortality.</td>
<td>Diarrhea, GI upset, transaminitis.</td>
</tr>
<tr>
<td>Pirfenidone</td>
<td>ASCEND/CAPACITY</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><img alt="" src="../_attachments/Pasted%20image%2020231010194552.png" /></p>
<p>Both are likely equally effective - halves the rate of progression over time.</p>
<h3 id="immunomodulation-in-ipf">Immunomodulation in IPF</h3>
<p>There is <em>no role for long-term immunosuppression in IPF</em>, given increased mortality (per <strong>PANTHER-IPF</strong> trial which examined prednisone, azathioprine, and NAC).</p>
<h2 id="transplant-referral">Transplant Referral</h2>
<p>Consider early referral for IPF and fibrotic NSIP. The criteria are:
- FVC &lt; 80%
- DLCO &lt; 40%
- Needs oxygen
- Failed pharmacotherapy</p>
<h1 id="references">References</h1>
<ol>
<li>IMR Slides 2021</li>
<li>Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. <em>New England Journal of Medicine</em>. 2012;366(21):1968-1977. doi:<a href="https://doi.org/10.1056/NEJMoa1113354">10.1056/NEJMoa1113354</a></li>
<li><a href="https://www.wikijournalclub.org/wiki/INPULSIS_Trials">INPULSIS Trials - Wiki Journal Club</a>, Richeldi L, du Bois RM, Raghu G, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. <em>New England Journal of Medicine</em>. 2014;370(22):2071-2082. doi:<a href="https://doi.org/10.1056/NEJMoa1402584">10.1056/NEJMoa1402584</a></li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Interstitial%20Lung%20Disease/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Interstitial%20Lung%20Disease/" class="btn btn-xs btn-link">
        Classification of ILDs
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Hypersensitivity%20Pneumonitis/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Hypersensitivity%20Pneumonitis/" class="btn btn-xs btn-link">
        Hypersensitivity Pneumonitis
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>